<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-05-18T16:14:20Z</responseDate><request verb="GetRecord" identifier="oai:uvadoc.uva.es:10324/55602" metadataPrefix="mods">https://uvadoc.uva.es/oai/request</request><GetRecord><record><header><identifier>oai:uvadoc.uva.es:10324/55602</identifier><datestamp>2025-02-13T10:09:32Z</datestamp><setSpec>com_10324_40357</setSpec><setSpec>com_10324_952</setSpec><setSpec>com_10324_894</setSpec><setSpec>col_10324_40358</setSpec></header><metadata><mods:mods xmlns:mods="http://www.loc.gov/mods/v3" xmlns:doc="http://www.lyncode.com/xoai" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
<mods:name>
<mods:namePart>Katsinas, Nicolaos</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Gehlsen, Uta</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>García Posadas, Laura</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Rodríguez Rojo, Soraya</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Steven, Philipp</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>González García, María Jesús</mods:namePart>
</mods:name>
<mods:name>
<mods:namePart>Enriquez De Salamanca Aladro, Amalia</mods:namePart>
</mods:name>
<mods:extension>
<mods:dateAvailable encoding="iso8601">2022-09-23T08:07:58Z</mods:dateAvailable>
</mods:extension>
<mods:extension>
<mods:dateAccessioned encoding="iso8601">2022-09-23T08:07:58Z</mods:dateAccessioned>
</mods:extension>
<mods:originInfo>
<mods:dateIssued encoding="iso8601">2022</mods:dateIssued>
</mods:originInfo>
<mods:identifier type="citation">Journal of Clinical Medicine, 2022, Vol. 11, Nº. 16, 17 pp.</mods:identifier>
<mods:identifier type="issn">2077-0383</mods:identifier>
<mods:identifier type="uri">https://uvadoc.uva.es/handle/10324/55602</mods:identifier>
<mods:identifier type="doi">10.3390/jcm11164703</mods:identifier>
<mods:identifier type="publicationfirstpage">1</mods:identifier>
<mods:identifier type="publicationissue">16</mods:identifier>
<mods:identifier type="publicationlastpage">17</mods:identifier>
<mods:identifier type="publicationtitle">Journal of Clinical Medicine</mods:identifier>
<mods:identifier type="publicationvolume">11</mods:identifier>
<mods:identifier type="essn">2077-0383</mods:identifier>
<mods:abstract>Dry eye (DED) is a prevalent disease with immune-mediated inflammation as the principal pathophysiological etiology. Olive pomace, the major by-product of the olive oil industry, is rich in high-value polyphenols. Their anti-inflammatory and immunomodulatory activities were determined on human CD4+ T cells (hTCD4+) and in a DED animal model. The viability of hTCD4+ cells isolated from peripheral blood and activated with phytohemagglutinin-M was evaluated after treatment for 48 h with an olive pomace extract (OPT3, 0.10–0.40 mg/mL) and its major compound, hydroxytyrosol (25–100 μM). Regarding the DED animal model, 100 μM hydroxytyrosol, 0.20 mg/mL OPT3, or vehicle (borate buffer) were topically administered to 14 days-desiccating stress-exposed (constant airflow/scopolamine administration) C57BL/6 mice. Tear volume, corneal fluorescein staining (CFS), CD4+, and CD8+ T cell count in lymph nodes (flow cytometry), and IP-10 and TNF-α gene expression (qRT-PCR) in the cornea, conjunctiva, and lacrimal glands were evaluated. OPT3 (0.2–0.4 mg/mL) and hydroxytyrosol (100 μM) significantly reduced hTCD4+ proliferation. In mice, both treatments reduced lacrimal gland IP-10 gene expression. OPT3 also decreased CFS, and conjunctival IP-10 and corneal TNF-α gene expression. In lymph nodes, hydroxytyrosol reduced CD3+, OPT3, and CD8+ count. Thus, a high-value application as a promising DED protection was proposed for olive pomace.</mods:abstract>
<mods:language>
<mods:languageTerm>eng</mods:languageTerm>
</mods:language>
<mods:accessCondition type="useAndReproduction">info:eu-repo/semantics/openAccess</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by/4.0/</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">© 2022 The Authors</mods:accessCondition>
<mods:accessCondition type="useAndReproduction">Atribución 4.0 Internacional</mods:accessCondition>
<mods:subject>
<mods:topic>Ojo - Enfermedades y defectos - Tratamiento</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Síndrome de ojo seco</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Aceite de oliva</mods:topic>
</mods:subject>
<mods:subject>
<mods:topic>Aceite de oliva - Análisis</mods:topic>
</mods:subject>
<mods:titleInfo>
<mods:title>Olive pomace phenolic compounds: from an agro-industrial by-product to a promising ocular surface protection for dry eye disease</mods:title>
</mods:titleInfo>
<mods:genre>info:eu-repo/semantics/article</mods:genre>
</mods:mods></metadata></record></GetRecord></OAI-PMH>